Prevalence of COPD in our lung cancer population, compared to controls

  • Research type

    Research Study

  • Full title

    Cross-sectional study to compare the prevalence of chronic obstructive pulmonary disease (COPD) in patients newly diagnosed with lung cancer, compared to controls

  • IRAS ID

    171508

  • Contact name

    Tariq Sethi

  • Contact email

    tariq.sethi@kcl.ac.uk

  • Sponsor organisation

    Guy's and St Thomas NHS Foundation Trust

  • Duration of Study in the UK

    0 years, 5 months, 2 days

  • Research summary

    Chronic obstructive pulmonary disease (COPD) is a serious illness overwhelmingly resulting from tobacco smoking. It is responsible for a substantial reduction in both quality of life and life expectancy. Lung cancer is another serious consequence of smoking that is responsible for around a million deaths worldwide annually. Not all smokers develop COPD or lung cancer. However, there is evidence that COPD is more common in patients who are diagnosed with lung cancer.

    COPD is characterised by two main processes - airway inflammation (bronchitis) and airspace destruction (emphysema). Inflammation is known to be harmful and is likely to play a role in the development of cancer. It is possible that COPD increases the risk of lung cancer, even independent of smoking exposure. However, as there are very few patients with COPD or lung cancer that have not smoked, this has been difficult to assess.

    We know little about the prevalence of COPD in our lung cancer population here and would like to measure this in patients who are newly diagnosed with lung cancer. This would be done by recording their lung function results when they attend the lung cancer clinic (which are already measured) to establish whether or not they have COPD. We would also review their X ray and/or computed tomography (CT) scan results to establish whether or not they had emphysema.

    We would then like to compare the prevalence of COPD in our newly diagnosed lung cancer patients to controls. Our controls would be patients who were referred to the smoking cessation service. We would ask these patients to undergo brief lung function testing (spirometry) if this had not already been performed. This would allow us to determine whether or not they had COPD. We would also ask these patients for details of their smoking history.

  • REC name

    Yorkshire & The Humber - South Yorkshire Research Ethics Committee

  • REC reference

    15/YH/0091

  • Date of REC Opinion

    12 Mar 2015

  • REC opinion

    Further Information Favourable Opinion